|
시장보고서
상품코드
1964225
결절성 피부병 백신 시장 규모, 점유율, 성장 분석 : 백신 유형별, 투여 경로별, 대상 동물별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Lumpy Skin Disease Vaccines Market Size, Share, and Growth Analysis, By Vaccine Type, By Administration Route, By Target Animal, By End-User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 결절성 피부병 백신 시장 규모는 2024년에 27억 달러로 평가되었고, 2025년 28억 4,000만 달러에서 2033년까지 41억 9,000만 달러로 성장할 전망입니다. 또한 예측 기간(2026-2033년) CAGR은 5.0%를 나타낼 것으로 예측됩니다.
세계 소의 발생률 증가와 지리적 확대로 인해 예방 대책과 백신 접종 대응 강화가 요구되고 있는 가운데, 세계 거대수포성 피부병 백신 시장은 주로 소의 발생률 증가와 지리적 확장에 의해 주도되고 있습니다. 이 시장에는 생백신, 불활성화 백신 등 다양한 백신 유형과 집단 예방접종 캠페인을 위한 물류 및 서비스 지원이 포함됩니다. 발생은 생산 손실, 무역 제한, 동물 복지 문제를 야기합니다. 지역적 대응에서 지역 간 협력적 백신 접종 활동으로의 전환은 아시아, 유럽 등의 지역에서 감시체계 강화와 콜드체인 물류 개선에 초점을 맞춘 노력이 확대되고 있음을 보여줍니다. 제조업체는 현장 배포를 단순화하기 위해 내열성 1회 투여 제제에 대한 투자를 진행하고 있습니다. AI 기술은 모니터링과 유통을 더욱 최적화하고, 감지 효율을 높이고, 적시에 백신 접종을 보장하여 궁극적으로 시장 성장을 가속하고 있습니다.
세계 피부병 백신 시장을 이끄는 요인들
피부병 백신에 대한 수요는 이 질병이 풍토병으로 존재하는 지역에서의 예방접종 캠페인의 확대에 의해 크게 견인되고 있습니다. 이러한 노력은 자원의 효과적인 조정, 수의학 서비스 참여, 소의 예방접종 우선순위를 높이고 백신 접종률 향상으로 이어졌습니다. 정부 및 지원 단체의 지원은 콜드체인 인프라 강화, 인력 양성, 보급 활동 개선에 중요한 역할을 하고 있으며, 농가에 백신을 광범위하게 보급하는 데 중요한 역할을 하고 있습니다. 효율화된 물류와 체계적인 집단 예방접종 활동은 접근 장벽을 해소하고 예방접종 결과에 대한 신뢰도를 높이며, 궁극적으로 공공 및 민간 부문의 지속적인 캠페인 실시와 조달 계약을 촉진할 것입니다. 이는 시장의 지속적인 성장을 가속하고 제조업체의 생산 능력 강화에 도움이 될 것입니다.
세계 피부 결절성 질환 백신 시장 성장 억제요인
규제 당국의 승인과 관련된 복잡성과 지연은 새로운 피부병 백신을 적시에 도입하는 데 심각한 문제를 야기합니다. 이러한 복잡성은 평가 기간을 연장하고, 개발자에게 불확실성을 야기합니다. 또한, 국가마다 다른 등록 요건과 신청 서류에 대한 기대치로 인해 광범위한 현지 조사와 추가 자료가 요구되어 자원 수요가 증가하여 중소 제조업체를 저해할 수 있습니다. 승인 절차가 길어지면 조달 및 백신 접종 프로그램 실행을 더욱 방해하고 도입의 추진력을 약화시키며 제조업체의 수익성을 제한할 수 있습니다. 이러한 불확실성은 연구개발에 대한 투자 의욕을 떨어뜨릴 수 있으며, 그 결과 가장 영향을 많이 받는 지역에 개선된 백신공급이 늦어질 수 있습니다.
세계 피부병 백신 시장 동향
세계 피부병 백신 시장에서는 현지 생산 능력을 강화하는 경향이 두드러지게 나타나고 있습니다. 각 제조업체들은 대응력과 공급망 복원력을 강화하기 위해 피해지역과 가까운 생산시설을 우선적으로 정비하고 있습니다. 이러한 전략적 전환은 원격지 공급업체에 대한 의존도를 낮출 뿐만 아니라, 현지 기업 및 정부와의 협력을 촉진합니다. 기술 이전과 인재 육성에 대한 투자를 통해 기업은 백신 생산을 효율적으로 확대하고, 지역 병원체 균주 특성에 대응하며, 다양한 규제 상황을 극복하고 있습니다. 이러한 노력은 동물 의료 서비스 분야의 채용을 촉진하고, 시장에서의 지역 밀착형 가치 창출을 통해 지속 가능한 성장을 도모하고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 결절성 피부병 백신 시장 규모 : 백신 유형별&CAGR(2026-2033)
세계의 결절성 피부병 백신 시장 규모 : 투여 경로별&CAGR(2026-2033)
세계의 결절성 피부병 백신 시장 규모 : 대상 동물별&CAGR(2026-2033)
세계의 결절성 피부병 백신 시장 규모 : 최종사용자별&CAGR(2026-2033)
세계의 결절성 피부병 백신 시장 규모&CAGR(2026-2033)
경쟁 정보
주요 기업 개요
결론과 제안
LSH 26.03.19Global Lumpy Skin Disease Vaccines Market size was valued at USD 2.7 Billion in 2024 and is poised to grow from USD 2.84 Billion in 2025 to USD 4.19 Billion by 2033, growing at a CAGR of 5.0% during the forecast period (2026-2033).
The global market for lumpy skin disease vaccines is primarily driven by the increasing incidence and geographic spread of outbreaks among cattle, necessitating enhanced preventive measures and vaccination responses. This market includes various vaccine types such as live attenuated and inactivated formulations alongside logistical and service support for mass immunization campaigns. Outbreaks lead to substantial production losses, trade restrictions, and animal welfare issues. The evolution from localized responses to coordinated transregional vaccination efforts illustrates growing efforts in regions like Asia and Europe, with a focus on enhanced surveillance and improved cold chain logistics. Manufacturers are investing in thermostable, single-dose formulations for simpler field deployment. AI technology is further optimizing surveillance and distribution, enhancing detection efficiency, and ensuring timely vaccination, ultimately facilitating market growth.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Lumpy Skin Disease Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Lumpy Skin Disease Vaccines Market Segments Analysis
Global lumpy skin disease vaccines market is segmented by vaccine type, administration route, target animal, end-user and region. Based on vaccine type, the market is segmented into Live Attenuated Vaccines, Inactivated Vaccines and Recombinant Vaccines. Based on administration route, the market is segmented into Intramuscular, Subcutaneous and Oral. Based on target animal, the market is segmented into Cattle, Buffalo and Others. Based on end-user, the market is segmented into Veterinary Clinics, Livestock Farmers and Research Institutions. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Lumpy Skin Disease Vaccines Market
The demand for lumpy skin disease vaccines is significantly driven by the expansion of vaccination campaigns in regions where the disease is endemic. These initiatives effectively coordinate resources, involve veterinary services, and prioritize the immunization of cattle, leading to increased vaccine uptake. Support from governments and donors plays a crucial role in enhancing cold chain infrastructure, training personnel, and improving outreach, which facilitates wider distribution of vaccines to farmers. Streamlined logistics and organized mass vaccination efforts help eliminate access barriers and foster trust in vaccination results, ultimately encouraging repeat campaigns and procurement commitments from both public and private sectors, thus promoting ongoing market growth and motivating manufacturers to enhance production capacities.
Restraints in the Global Lumpy Skin Disease Vaccines Market
The complexities and delays associated with regulatory approvals pose significant challenges to the timely introduction of new lumpy skin disease vaccines. These intricacies extend evaluation periods and create uncertainty for developers. Additionally, varying national registration requirements and differing dossier expectations demand extensive local studies or supplementary data, which increases resource demands and can deter smaller manufacturers. Protracted authorization processes further hinder procurement and the implementation of vaccination programs, diminishing the momentum for adoption and restricting manufacturers' revenue potential. Such uncertainty may discourage investment in research and development, consequently delaying the availability of enhanced vaccines to the regions most impacted.
Market Trends of the Global Lumpy Skin Disease Vaccines Market
The Global Lumpy Skin Disease Vaccines market is witnessing a notable trend towards localized manufacturing capacity. As manufacturers seek to enhance their responsiveness and supply chain resilience, they are prioritizing production facilities closer to affected regions. This strategic shift not only reduces reliance on distant suppliers but also fosters collaborations with local firms and governments. By investing in technology transfer and workforce development, companies are scaling vaccine production efficiently, addressing regional strain profiles, and navigating varied regulatory landscapes. These initiatives are driving adoption among veterinary services and promoting sustainable growth through localized value creation in the market.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Lumpy Skin Disease Vaccines Market Size by Vaccine Type & CAGR (2026-2033)
- Market Overview
- Live Attenuated Vaccines
- Inactivated Vaccines
- Recombinant Vaccines
Global Lumpy Skin Disease Vaccines Market Size by Administration Route & CAGR (2026-2033)
- Market Overview
- Intramuscular
- Subcutaneous
- Oral
Global Lumpy Skin Disease Vaccines Market Size by Target Animal & CAGR (2026-2033)
- Market Overview
- Cattle
- Buffalo
- Others
Global Lumpy Skin Disease Vaccines Market Size by End-User & CAGR (2026-2033)
- Market Overview
- Veterinary Clinics
- Livestock Farmers
- Research Institutions
Global Lumpy Skin Disease Vaccines Market Size & CAGR (2026-2033)
- North America (Vaccine Type, Administration Route, Target Animal, End-User)
- US
- Canada
- Europe (Vaccine Type, Administration Route, Target Animal, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Vaccine Type, Administration Route, Target Animal, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Vaccine Type, Administration Route, Target Animal, End-User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Vaccine Type, Administration Route, Target Animal, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Zoetis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck Animal Health
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Elanco Animal Health
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Virbac
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ceva Sante Animale
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Oxford Immunotec
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Vetoquinol
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Huvepharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- iO Veterinary
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Algenex
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- MSD Animal Health
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AgriLabs
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Intervet
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bioniche Animal Health
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- KindredBio
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Indian Immunologicals Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Adimmune Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biovac
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kye Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
